Sign in

    Richard Miller • Cantor Fitzgerald

    Richard Miller's questions to ADMA Biologics Inc (ADMA) leadership

    Richard Miller's questions to ADMA Biologics Inc (ADMA) leadership • Q2 2025

    Question

    Richard Miller of Cantor Fitzgerald inquired about current physician utilization trends for Ascentive and sought a technical explanation of the company's new yield enhancement manufacturing process.

    Answer

    CEO Adam Grossman stated that Ascentive utilization trends remain consistent, with new patient starts and switches from standard IG therapies continuing. He explained that the yield enhancement process involves repurifying a previously discarded waste stream containing IgG, using chromatography and filtration, and then blending it back into the main process, resulting in a 20% or greater increase in bulk IG yield.

    Ask Fintool Equity Research AI

    Richard Miller's questions to PTC Therapeutics Inc (PTCT) leadership

    Richard Miller's questions to PTC Therapeutics Inc (PTCT) leadership • Q3 2024

    Question

    Richard Miller of Cantor Fitzgerald inquired about the timeline for updates following the Huntington's disease Type C meeting and how the FDA might evaluate the STRIDE registry data for the Translarna resubmission.

    Answer

    CEO Matthew Klein responded that the Huntington's meeting is scheduled for December 2024, with updates to follow once clarity is received. For Translarna, he emphasized the strength of the data package, noting Study 41 showed significant benefit and the STRIDE registry provided confirmatory long-term evidence of a 3.5-year delay in loss of ambulation, making it a compelling application regardless of regulatory flexibility.

    Ask Fintool Equity Research AI